Michaela Granzow
Bonn, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor.
Journal: Scientific reports
Published: October 05, 2018
Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.
Journal: Scientific reports
Published: February 18, 2015
Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.
Journal: Hepatology (Baltimore, Md.)
Published: August 28, 2013
Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats.
Journal: Frontiers in physiology
Published: May 29, 2013
Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis.
Journal: Gastroenterology
Published: November 01, 2012
Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats.
Journal: Laboratory investigation; a journal of technical methods and pathology
Published: August 15, 2012
The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes.
Journal: American journal of physiology. Gastrointestinal and liver physiology
Published: February 04, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026